The genus Moraxella comprises approximately 20 species of aerobic, non-motile, oxidase-positive, and gram-negative coccobacilli. Besides M. catarrhalis, a well-known pathogen, M. atlantae, M. canis, M. lacunata, M. lincolnii, M. nonliquefaciens, and M. osloensis are also occasionally isolated from clinical samples [1] . M. osloensis is a commensal microorganism in the human respiratory tract, but has also been reported as a rare causative pathogen in human infections [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Here, we report a case of M. osloensis bacteremia in a patient with a hematologic malignancy. To our knowledge, this is the first report of M. osloensis bacteremia in Korea.
/L; Creactive protein level, 6 .48 mg/dL; blood urea nitrogen (BUN)/ creatinine, 15/1.2 mg/dL; and total protein/albumin, 6.8/3.6 g/ dL. A total of four blood culture sets were collected from two separate peripheral veins and central venous catheter. There were no abnormalities in the chest radiographic images, but paranasal sinus radiographic imaging indicated a suspected maxillary sinusitis. Therefore, empirical antibiotic therapy with intravenous ampicillin-sulbactam was administered.
Bacterial growth was detected in an aerobic culture bottle that contained the blood from the central venous catheter after 1 day of incubation, and in the other 3 aerobic culture bottles after 2 days of incubation (Fig. 1A) . The broths from positive culture bottles were inoculated onto blood agar plates (BAPs) and MacConkey agar plates (MACs) that were subsequently incubated for 24 hr at 35°C in a 5% CO2 atmosphere. Whereas no colony was observed on the MACs, grey-white colored, non-hemolytic colonies grew on the BAPs (Fig. 1B) and gram-negative coccobacilli were observed from gram stain smear preparations (Fig.  1C) . The isolates were oxidase-positive and indole-negative.
Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Bruker Daltonik GmbH, Bremen, Germany) and Vitek2 GN system (bioMérieux, Marcy l'Etoile, France), the organism was suboptimally identified as M. osloensis, with a score of 1.885 in the Bruker system and with a 50% probability in the Vitek2 system.
To confirm the identity of the isolate, 16S rRNA sequence analysis was performed on the MicroSeq 500 system (Applied Biosystems, Foster City, CA, USA), using PCR and sequencing kits with universal primers designed to cover all bacteria. The se-quences were analyzed with an ABI PRISM 3730 Series DNA Analyzer (Applied Biosystems). The first 500 bp of the 16S rRNA gene sequence from the isolate shared 99.6% identity with the GenBank sequence AY043376 (M. osloensis) and 99.0% identity with the GenBank sequence KC494325 (Enhydrobacter aerosaccus).
Antimicrobial susceptibility was tested with the AST-N222 card from the Vitek 2 system (bioMérieux). Using the CLSI breakpoints for other non-Enterobacteriaceae for the interpretation [14] , the isolate was determined susceptible to aztreonam, cefepime, ceftazidime, ciprofloxacin, gentamicin, imipenem, meropenem, piperacillin, and trimethoprim-sulfamethoxazole.
Intravenous ampicillin-sulbactam treatment was maintained, and follow-up blood cultures from the peripheral veins and central venous catheter on day 3 were negative. The patient was successfully treated with a 10-day course of intravenous ampicillin-sulbactam and subsequently began consolidation chemotherapy for AML.
Despite the unique biochemical characteristics of M. osloensis, which include acetate alkalinization, ethylene glycol acidification, and desferrioxamine resistance, species-level biochemical identification is difficult because of the overall lack of biochemical differences among the Moraxella species [1] . Although only 2 reported isolates besides the present case have been identified by MALDI-TOF MS, this method suboptimally identified M. osloensis; one isolate was identified as M. osloensis with a score of < 1.4 in the Bruker system [15] , and the other was identified as M. osloensis without score information in the Bruker system, but as Moraxella sp. in the SARAMIS system [16] . The present isolate analyzed by Bruker system showed better score than previous cases but species-level identification for M. osloensis by MALDI-TOF MS still seem to be insufficient. At present, 16S rRNA sequence analysis is the only reliable method that can be used for species-level identification [2] [3] [4] [5] [6] [7] [8] [9] . With this method, the blood isolate in the present case was confirmed to be M. osloensis.
Although M. osloensis is a rare pathogen in humans, it can be involved in bacteremia, central venous catheter-related infections, endocarditis, endophthalmitis, meningitis, osteomyelitis, pneumonia, and septic arthritis [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . In 2010, Roh et al. [7] A B C [2, 6, 8, 9] . Accordingly, the present case involved M. osloensis bacteremia in an immunocompromised patient who had been diagnosed as AML. Regarding treatment, M. osloensis is susceptible to penicillin, cephalosporins, and aminoglycosides [17, 18] . The isolated strain described in this report was susceptible to the majority of antimicrobial agents, and therefore the patient was successfully treated with a 10-day course of ampicillin-sulbactam.
In conclusion, we report the first case of M. osloensis bacteremia in Korea. The present findings indicate that M. osloensis can be an opportunistic pathogen in humans, especially in immunocompromised patients such as those with hematologic malignancies.
